Skip Navigation

Annals of Oncology 2006 17(2):183-184; doi:10.1093/annonc/mdj141
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Partridge, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Partridge, A. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

editorial

Non-adherence to endocrine therapy for breast cancer

A. H. Partridge

Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

(E-mail: ahpartridge@partners.org)

The first 10% of the full text of this article appears below.

Women with breast cancer often face a variety of decisions regarding their treatment at diagnosis and in follow-up. When considering endocrine therapy, whether for early or advanced breast cancer, there are several options available, with differing side-effects and routes of administration, from which a woman and her health care providers must choose. In this issue of Annals of Oncology, Professor Fallowfield and colleagues elucidate preferences of women with breast cancer regarding endocrine therapy, considering between tablet and injection formulations. Through interviews with 208 women with a history of early or stable advanced breast cancer, the investigators found that most women (63%) preferred tablet therapy to injections, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
V. H. C. Bramwell, K. I. Pritchard, D. Tu, K. Tonkin, H. Vachhrajani, T. A. Vandenberg, J. Robert, A. Arnold, S. E. O'Reilly, B. Graham, et al.
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)
Ann. Onc., July 23, 2009; (2009) mdp326v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Ziller, M. Kalder, U.-S. Albert, W. Holzhauer, M. Ziller, U. Wagner, and P. Hadji
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ann. Onc., March 1, 2009; 20(3): 431 - 436.
[Abstract] [Full Text] [PDF]